Yellow Fever Human Infection Model With YF-17D

• Status: Recruiting
• Trial end date: 2024-03-01
• Target enrollment: 0
• Participant gender: All

Summary

No antiviral treatment exists for yellow fever, only supportive care, and therefore we rely on prevention through vaccination. Although this vaccine is very effective, stockpiles are insufficient in outbreak situations and some people have a contraindication to be vaccinated. For those who are unprotected and at risk of yellow fever infection, treatment could be life saving.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Leiden University Medical Center
• Collaborator: The International Society of Travel Medicine
• Treatments: Vaccines

Criteria

Inclusion Criteria:

• age 18-50 years

Exclusion Criteria:

• contraindication to receive YF-17D (immune deficiency, thymus illness)

• previous YF vaccination

• pregnancy

• chicken egg allergy

• hypersensitivity to any other substance in the YF-17D vaccine

• interval of < 4 weeks of another live attenuated vaccine